Pharmafile Logo
Pharmafocus logo
Advanced Search

farxiga

Showing 15 posts of 17 posts found.

AstraZeneca’s Farxiga approved to reduce risk of cardiovascular death

May 9, 2023
Medical Communications AstraZeneca, Cardiology, FDA, cvd, farxiga, heart failure

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular …

News
AstraZeneca sign

AstraZeneca’s Farxiga falls short in Phase III trials for treatment of COVID-19

April 13, 2021
Manufacturing and Production AstraZeneca, COVID-19, covid-19 treatment, farxiga, pharma, pharma news

AstraZeneca’s Farxiga drug, usually used in patients with diabetes, did not show statistical significance in the Phase III trial into …

News
astrazeneca_sign_sky

AstraZeneca’s Farxiga granted Priority Review by FDA

January 6, 2021
Research and Development AstraZeneca, FDA, farxiga

AstraZeneca’s Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney …

News
shutterstock_159488225

Farxiga smashes all goals in Phase 3 chronic kidney disease trial, says AstraZeneca

July 28, 2020
Manufacturing and Production, Research and Development AstraZeneca, farxiga

AstraZeneca has teased new data from a Phase 3 study of its sodium-glucose co-transporter-2 (SGLT2) inhibitor Farxiga (dapagliflozin) in the …

News
astrazeneca_sign_sky

AstraZeneca secures accelerated FDA review for Farxiga for for CV death following heart attacks

July 17, 2020
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, FDA, farxiga, fast track

AstraZeneca has made it known that Farxiga (dapagliflozin) has secured Fast Track Designation from the FDA for the reduction of …

News
fda2outsideweb

AZ’s Farxiga becomes first FDA-approved SGLT2 inhibitor for heart failure with reduced ejection fraction

May 6, 2020
Research and Development, Sales and Marketing AstraZeneca, FDA, farxiga, heart failure

The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular …

News
5204602349_c87b204860_b

FDA gives a priority review for key heart failure drug Farxiga

January 6, 2020
Sales and Marketing AstraZeneca, Heart Failures, farxiga

The FDA has accepted a New Drug Application (sNDA) and has granted a priority review for AstraZeneca’s drug Farxiga (dapagliflozin) …

News
astrazeneca-sign

AstraZeneca’s Farxiga meets Phase 3 primary endpoint in heart failure

August 20, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, cardiovascular disease, farxiga

New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite …

News
astrazeneca_building_white

AstraZeneca’s Farxiga fails to get FDA approval for patients with Type 1 diabetes

July 15, 2019
Sales and Marketing AstraZeneca, EMA, FDA, US, diabetes, farxiga

The FDA had said it will not approve AstraZeneca’s diabetes drug Farxiga for use as a supplement to insulin in …

News
astrazeneca_building_white

AstraZeneca’s Phase 3 Farxiga data impresses in type 2 diabetes

June 11, 2019
Manufacturing and Production, Research and Development AstraZeneca, diabetes, farxiga, pharma, type 2 diabetes

AstraZeneca has presented new Phase 3 data at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco on …

News
astrazeneca_plaque

AZ’s Farxiga reduces major adverse cardiovascular event risk in type 2 diabetes, new data shows

March 19, 2019
Manufacturing and Production, Research and Development AstraZeneca, cardiovascular, farxiga, pharma

AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing …

News
astrazeneca_building_white

AZ’s Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study

November 12, 2018
Research and Development, Sales and Marketing AstraZeneca, cardiovascular, farxiga, pharma

AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart Association (AHA) …

News
astrazeneca-sign

AstraZeneca’s Farxiga cuts heart risk in type 2 diabetes patients

September 24, 2018
Research and Development, Sales and Marketing AstraZeneca, diabetes, farxiga, pharma

AstraZeneca has unveiled new Phase 3 data for its SGLT2 inhibitor Farxiga (dapagliflozin), showing with the drug demonstrating positive findings …

News
astrazeneca_logo_building

AstraZeneca’s Forxiga displays potential in type 1 diabetes

September 14, 2017
Research and Development AstraZeneca, Forxiga, biotech, drugs, farxiga, pharma, pharmaceutical

Forxiga is AstraZeneca’s treatment for those living with type 2 diabetes but the results from a new trial have found …

News

FDA issues warnings on Janssen, AstraZeneca diabetes drugs

June 15, 2016
Research and Development, Sales and Marketing AstraZeneca, FDA, Janssen, farxiga, invokana

The US Food and Drug Administration has issued a warning of the risk of acute kidney injury for the type-2 …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024